Study of forced degradation behavior of pramlintide acetate by HPLC and LC–MS

Pramlintide acetate (Symlin(®)), a synthetic analogue of the human hormone amylin. It was approved in March 2005 as a subcutaneous injection for the adjunctive treatment of patients who have type 1 or 2 diabetes mellitus. The objective of current investigation was to study the degradation behavior o...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Yu, Li, Yuan-Bo, Tai, Zheng-Fu, Xie, Yi-Peng, Pu, Xu-Feng, Gao, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taiwan Food and Drug Administration 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332648/
https://www.ncbi.nlm.nih.gov/pubmed/29389581
http://dx.doi.org/10.1016/j.jfda.2017.07.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332648/
https://www.ncbi.nlm.nih.gov/pubmed/29389581
http://dx.doi.org/10.1016/j.jfda.2017.07.009

Ejemplares similares